Current studentsExisting staffContact us
 

Resistance to anti-HCV protease inhibitors

Simple item page
dc.contributor.authorThompson, A.J.
dc.contributor.authorLocarnini, S.A.
dc.contributor.authorBeard, M.R.
dc.date.issued2011
dc.description.abstractThe era of direct acting antiviral therapy for HCV infection has dawned with the recent approval of the NS3 protease inhibitors telaprevir and boceprevir. The development of DAA therapy is an exciting advance for clinicians and patients, but it will also bring new challenges. For the first time, drug resistance has become an issue to consider in the management of HCV. This brief review summarizes the current literature concerning resistance to the HCV NS3 protease inhibitors, both experimental and clinical, and identifies the key questions facing the field.
dc.description.statementofresponsibilityAlexander J Thompson, Stephen A Locarnini, and Michael R Beard
dc.identifier.citationCurrent Opinion in Virology, 2011; 1(6):599-606
dc.identifier.doi10.1016/j.coviro.2011.10.001
dc.identifier.issn1879-6257
dc.identifier.issn1879-6265
dc.identifier.orcidBeard, M.R. [0000-0002-4106-1016]
dc.identifier.urihttp://hdl.handle.net/2440/89300
dc.language.isoen
dc.publisherElsevier
dc.rights© 2011 Elsevier B.V. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.coviro.2011.10.001
dc.subjectHumans
dc.subjectHepacivirus
dc.subjectHepatitis C, Chronic
dc.subjectProline
dc.subjectOligopeptides
dc.subjectViral Nonstructural Proteins
dc.subjectProtease Inhibitors
dc.subjectDrug Resistance, Viral
dc.subjectVirus Replication
dc.subjectModels, Molecular
dc.titleResistance to anti-HCV protease inhibitors
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Microbiology and Immunology publications